Helus Pharma Inc (HELP) — Titan Protect Analysis

HELP

Helus Pharma Inc

Healthcare · ·

$4.15

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$221M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.39

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-55.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$45.47

+996% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 8 analysts covering this stock

About Helus Pharma Inc

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterate

https://cybin.com

Country: Canada Employees: 50 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.270

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0740

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.572

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-37.8%

Historical annualised return based on price data

Max Drawdown

-66.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.81

Less volatile than the market — more defensive

52W High

$9.83

58% below the year high

52W Low

$4.15

0% above the year low

Avg Volume

1,190,673

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.30

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-69,987,976

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-123,217,320

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$93.26

Target Median

$45.47

Target Low

$7.97

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go